Li Yan-bing, Zhu Hui-li, Yao Bin, Huang Zhi-min, Ou Xiang-zhong, Xiao Yi-bin, Weng Jian-ping
Department of Endocrinology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Zhonghua Yi Xue Za Zhi. 2005 Mar 9;85(9):602-5.
To investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on newly diagnosed type 2 diabetes and to identify the influencing factors for the curative effects of CSII.
138 newly diagnosed type 2 diabetic patients with fasting plasma glucose > 11.1 mmol/L were treated with CSII for 2 weeks. Intravenous glucose tolerance test (IVGTT) was performed before and after CSII. The target of glycemic control were fasting blood glucose < 6.1 mmol/L and postprandial blood glucose (PBG) < 8.0 mmol/L. The age, body mass index (BMI), fasting and postprandial plasma glucose, hemoglobin A(1C) (GHbA(1C)), Homa beta, Homa IR, area under the curve of insulin (AUC) during IVGTT were compared between the good glycemic control group and the inadequate glycemic control group.
After 2 weeks' CSII treatment, good glycemic control was achieved in 126 patients (group A) but not in the remaining 12 patients (group B). There were no differences in age, BMI, postprandial plasma glucose, GHbA(1C), and Homa IR between the two groups before and after CSII treatment. But the fasting plasma glucose was higher and Homa B was lower in group B than in group A before CSII treatment. The DeltaAUC (AUC after CSII subtracted from that before CSII) representing the recovery of beta-cell function was much greater in group A than in group B. The insulin dose of group B was significantly higher than that of the good glycemic control group.
More severe hyperglycemia and relative beta-cell function deficiency may be the main reasons responsible for not achieving good glycemic control in newly diagnosed type 2 diabetic patients with short-term intensive CSII treatment.
探讨短期持续皮下胰岛素输注(CSII)对新诊断2型糖尿病的疗效,并分析影响CSII疗效的因素。
138例新诊断的空腹血糖>11.1 mmol/L的2型糖尿病患者接受CSII治疗2周。在CSII治疗前后进行静脉葡萄糖耐量试验(IVGTT)。血糖控制目标为空腹血糖<6.1 mmol/L,餐后血糖(PBG)<8.0 mmol/L。比较血糖控制良好组和血糖控制不佳组的年龄、体重指数(BMI)、空腹及餐后血糖、糖化血红蛋白A1C(GHbA1C)、Homaβ、Homa胰岛素抵抗指数(Homa IR)、IVGTT期间胰岛素曲线下面积(AUC)。
CSII治疗2周后,126例患者(A组)血糖控制良好,其余12例患者(B组)血糖控制不佳。两组患者在CSII治疗前后的年龄、BMI、餐后血糖、GHbA1C及Homa IR方面无差异。但在CSII治疗前,B组的空腹血糖高于A组,Homaβ低于A组。代表β细胞功能恢复的DeltaAUC(CSII治疗后AUC减去治疗前AUC)在A组比B组大得多。B组的胰岛素剂量明显高于血糖控制良好组。
在新诊断的2型糖尿病患者中,短期强化CSII治疗未能实现良好血糖控制的主要原因可能是更严重的高血糖和相对的β细胞功能缺陷。